Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 2897 - 2904 of 12086 results
EXCLUSIVE RIGHTS: Intellectual Property — Blockchain, Cryptocurrency, and IP: What Does the Future Hold?
September 23, 2021| Podcast| Viewpoint
Regulatory Fees for Unlicensed Users and Large Technology Companies?
September 22, 2021| Blog| Viewpoint
Biden Administration Announces Changes to COVID-19 Travel Bans
September 22, 2021| Alert| Viewpoint
California Health Privacy Information Legislation Update
September 22, 2021| Blog| Viewpoint
9th Circuit Upholds California Bill Banning Mandatory Arbitration in Employment – Likely Headed for Supreme Court
September 22, 2021| Blog| Viewpoint
Mintz Nabs a Pair of Veteran Bankruptcy and Restructuring Lawyers
September 22, 2021| News
Deal Doctors: Coco, Preusker Move to Mintz
September 22, 2021| News
FTC Personal Health Records Breach Rule Applies to Health App and Connected Device Developers
September 21, 2021| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|